Article Text

Download PDFPDF
Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


In women at risk of preterm delivery, does magnesium sulphate provide neuroprotection for the fetus?

Review scope

Included studies compared magnesium sulphate (administered intravenously, intramuscularly, or orally) with placebo, no treatment, or an alternate treatment (control) as a neuroprotective agent for the fetus when given to women at risk of preterm delivery. Studies in which the primary aim was other than fetal neuroprotection (eg, treatment of pre-eclampsia or preterm labour) were included if long-term infant neurological outcomes were reported. Outcomes were fetal/infant death, cerebral palsy, neurological impairment, and maternal side effects (such as nausea, vomiting, headache, palpitations, and flushing).

Review methods

Cochrane Pregnancy and Childbirth Group’s Trials Register (which contains results of searches of Cochrane Central Register of Controlled Trials, Medline, 30 journals, and major conference proceedings) was searched in August 2008 for randomised controlled trials (RCTs). 5 articles describing 6 …

View Full Text


  • Source of funding: Australian National Health and Medical Research Council and Commonwealth Department of Health and Ageing.